ArticleAge and ageing2026
Adverse childhood experiences and sarcopenia: a prospective study embedded in the Canadian Longitudinal Study on Aging.
Article in Age and ageing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAdverse childhood experiences (ACEs), known to increase lifelong health risks, have recently been linked to frailty. This study examined whether ACEs predict the onset and progression of sarcopenia, a core component of the frailty phenotype.
methodsWe analysed 23 476 participants aged 45-85 years in the Canadian Longitudinal Study on Aging with 3-year follow-up (49.5% female; mean age 62.1 ± 9.9). Eight ACEs were assessed using validated retrospective instruments. Associations between ACE count and incident sarcopenia (revised European Working groups on Sarcopenia in Older People criteria) were evaluated using multivariable logistic regression, while changes in continuous sarcopenia components were assessed with lagged linear models adjusted for age, sex and ethnicity. Moderating effects of age, sex, ethnicity, depression (CESD ≥ 10) and socioeconomic position (education, income) were explored.
resultsOverall, 12.7% of participants reported a high ACE burden (≥3). Among 21 910 participants without baseline sarcopenia, 614 (2.8%) developed sarcopenia. Depression, but not sociodemographic factors, moderated the ACE-sarcopenia association. ACE count predicted incident sarcopenia among depressed participants [OR (odds ratio) = 1.10 (95% (confidence interval) CI: 1.02-1.20), P = .016], but not among nondepressed participants [OR = 0.98 (95% CI: 0.93-1.03), P = .399]. Depression also moderated ACE-related declines in lean muscle mass and handgrip strength. Post hoc analyses showed that ACE-related worsening of chair rise performance and gait speed was mediated by depression.
conclusionsACEs are associated with modest declines in muscle mass and function, with depression emerging as a key pathway linking early adversity to later-life sarcopenia. These findings highlight the need to integrate psychosocial history and mental health into risk stratification and preventive strategies for functional decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.